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1. Abbreviations 
 
AVR: aortic valve replacement 
BSA: body surface area 
CABG: coronary artery bypass grafting 
EOA: effective orifice area 
GOA: geometric orifice area 
IEOA indexed effective orifice area 
IGOA: indexed geometric orifice area 
LV: left ventricle  
LVEF: left ventricle ejection fraction 
NYHA: New York Heart Association  
PPM: patient-prosthesis mismatch 
SVD: structural valve deterioration 
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2. Introduction 
 
2.1 Aortic valve disease 
 
The aortic valve separates the left ventricle from the aorta. It is constituted by three 
leaflets attached to a crown shaped annulus (fig 1). 
 
 
Fig 1.The dissection shows the three aortic valve leaflets (1: left coronary leaflet; 2: 
right coronary leaflet; 3: non coronary leaflet) and their anatomical relation with the 
coronary arteries. From Robert H. Anderson, The surgical anatomy of the aortic root, 
doi:10.1510/mmcts.2006.002527  
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 Any condition which modifies the morphology and, consequently, the physiology of 
the aortic valve can be included at least in one of the two categories of aortic valve 
disease: aortic valve stenosis and aortic valve regurgitation
1
. 
The first condition, aortic valve stenosis, is a complex disease. About 2-7% of the 
population over 65 years of age is affected by its degenerative form
2
. Thus, as elderly 
people represent the fastest growing section of the population in western countries
3
, 
aortic stenosis is the most frequent heart valve disease in Europe and US
4
. Old patients 
with degenerative aortic stenosis represent a heterogeneous population with specific 
comorbidities. The pathogeneses of some of them, such as arterial hypertension, 
coronary artery disease or impaired left ventricle function, are interrelated. For this 
reason degenerative aortic stenosis has been defined as a “systemic disease”5. The 
second cause of aortic stenosis is rheumatic disease. 
Independently from the etiology, a stenotic aortic valve is characterized by diffuse 
leaflets thickening, fusion or calcification, with reduction of the orifice valve
6
 (fig. 2). 
 
Fig. 2. A: stenotic aortic valve exposed after transection of the ascending aorta. Note the 
fusion of the commissures (*). B: aortic leaflet after surgical excision. Note the severe 
spherical calcifications (*). (Photographic files of the author). 
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The decrease of the aortic valve orifice area results in progressively greater left 
ventricular pressure overload and left ventricular hypertrophy
7
.  Pressure overload  itself 
increases left ventricular afterload, impairing ejection performance. Afterload is 
generally quantified as wall stress (σ) which is governed by the law of Laplace, in 
which σ = pr/2t,  where “p” is left ventricular pressure, “r” is left ventricular radius, and 
“t” is left ventricular thickness. As pressure grows in the numerator of this equation it is 
offset by a rise in wall thickness (concentric left ventricular hypertrophy) in the 
denominator, keeping afterload (wall stress) normal (fig 3).  
 
 
 
 
Fig 3. (A) Eighty percent of the patients with severe aortic stenosis (AS) presents with 
left ventricle hypertrophy with normal ejection fraction and normal left ventricular (LV) 
volume. (B) Ten percent of patients with AS presents with severe hypertrophic LV 
remodeling with reduced LV volume. (C) Another 10% of patients with AS, shows LV 
dilatation with decreased ejection fraction. From Urso et al. Asymptomatic severe aortic 
stenosis: a reopened debate.  Med Clin (Barc), 2014 May 6;142(9):406-11.  
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Since afterload is a key determinant of ejection performance, its normalisation is 
important in maintaining normal ejection fraction and stroke volume
8
. Left ventricular 
hypertrophy has two hemodynamic consequences. First, it has been shown to decrease 
ventricular contractility and ejection performance
9
. Second, it leads to an abnormal 
coronary flow pattern and a decrease in coronary blood flow reserve leading to a state of 
relative myocardial ischemia
10
. The most frequent causes of aortic regurgitation are 
rheumatic disease, anuloaortic ectasia and endocarditis. In all these conditions, 
independently from the morphologic lesion, the competence of the aortic valve is 
affected. Patients with aortic regurgitation have combined volume and pressure 
overload of the left ventricle. Compensatory mechanisms are recruitment of preload 
reserve and LV hypertrophy
11
. 
The European Society of Cardiology/European Association of Cardiothoracic Surgery 
(ESC/EACTS) guidelines
12
 recommend aortic valve surgery in patients with severe 
aortic valve stenosis in presence of symptoms (dyspnoea, angina and syncope) or left 
ventricle dysfunction (left ventricle ejection fraction [LVEF] <50%).  Similarly, in 
patients with severe aortic regurgitation surgery is indicated in presence of symptoms 
(dyspnoea), or LV dysfunction (LVEF <50%) or LV dilatation (left ventricular end-
diastolic diameter > 70 mm). 
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2.2 Aortic valve replacement and aortic valve prosthesis 
 
The conventional surgical treatment of the aortic valve disease is aortic valve 
replacement (AVR), which produces LV hypertrophy regression
13
 by eliminating the 
pressure/volume overload. AVR is carried out on cardiopulmonary bypass and with 
arrested heart. Standard surgical accesses to the aortic valve are represented by 
sternotomy, ministernotomy, and right minithoracotomy with support of videoscopy.   
The standard procedure consists in excision of the valve leaflets, decalcification of the 
aortic annulus and implantation of a biological valve prosthesis or a mechanical valve 
prosthesis.  
The choice of the appropriate prosthetic valve has to take in consideration two factors. 
The first one is the evaluation of the span life of the prosthesis.  Bioprostheses can be 
divided, according to their design, in stented (with metallic or polymer supporting stent) 
and stentless and, according to their components, in porcine (made of 3 porcine aortic 
valve leaflets crosslinked with glutaraldehyde) and pericardial (made from sheets of 
bovine pericardium mounted inside or outside a supporting stent)
14
.  All bioprostheses, 
differently from the mechanical prostheses, undergo a process of structural valve 
deterioration, which represents the main determinant of their longevity. Indeed, the 
current guidelines by the European Association Cardiothoracic Surgery/ European 
Society of Cardiology suggest implanting aortic bioprosthesis in patients >65 years 
(class IIa), whose lifespan is supposed to be lower than the durability of the current 
bioprosthesis.  
The second factor to take in consideration in choosing the prosthetic valve is the 
anticoagulation treatment which is mandatory in patients receiving mechanical 
prostheses. These have been evolving from the first generation of caged ball prostheses 
9 
 
trough the second monoleaflet generation to the third bileaflet generation (fig. 4). Still, 
because of their high thrombogenicity, they require lifelong anticoagulation.  
 
 
 
Fig.4  Different types of prosthetic valves. A, Bileaflet mechanical valve (St Jude); B, 
monoleaflet mechanical valve (Medtronic Hall); C, caged ball valve (Starr-Edwards); D, 
stented porcine bioprosthesis (Medtronic Mosaic); E, stented pericardial bioprosthesis 
(Carpentier-Edwards Magna); F, stentless porcine bioprosthesis (Medtronic Freestyle); 
G, percutaneous bioprosthesis expanded over a balloon (Edwards Sapien); H, self-
expandable percutaneous bioprosthesis (CoreValve). From Pibarot P and Dumesnil JG 
Circulation. 2009 Feb 24;119(7):1034-48.  
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Recent data have shown that a growing proportion of patients undergoing AVR are 
represented by elderly patients
15
, who are considered to be high risk patients. 
Nonetheless, the surgical risk of AVR has been reported to be decreasing. This 
phenomenon is the so-called paradoxical risk (the number of patients with high 
operative risk increases, but the overall surgical risk, in fact, decreases, thanks to the 
improvement of surgical, anesthesiologist and intensive care procedures).
16
 This fact has 
been documented by the developers of the euroSCORE, a tool used to predict early 
mortality in patients undergoing cardiac surgery 
17
.  Recently the data of the Society for 
Cardiothoracic Surgery in Great Britain and Ireland National database, storing 41.227 
patients underwent AVR, have been published
18
. This database reports hospital 
mortality of 4.1% for the whole population and of 8.1% of for the patients > 80 years 
old. Octogenarian patients are the subject of a recent meta-analysis
19
  studying 13.261 
elderly patients who underwent AVR. This study reports a 30 days mortality of 6.7%. 
A relatively new therapeutic option for high risk patients with aortic stenosis is the 
transcatheter aortic valve implantation (TAVI). The TAVI is a percutaneous procedure, 
introduced in 2002
20
, which allows implantation of aortic biological stentless prosthesis. 
This technique is currently reserved for those patients whose high risk profile 
discourages the use of extracorporeal circulation, required by the standard AVR 
surgery.  TAVI needs to be performed in a hybrid operative suite by a dedicated 
multidisciplinary team, it is carried out under general anesthesia and it does not require 
extracorporeal circulation. TAVI can be performed by two approaches: retrograde and 
anterograde. The first one consists in the insertion of the delivery catheter through the 
common femoral artery. The catheter is progressed, under fluoroscopic and 
echocardiographic guide, to the aortic annulus, the aortic valve is ballooned, and the 
prosthesis is delivered. In the anterograde approach, the delivery catheter is inserted 
11 
 
though the LV apex, exposed by a small left anterior mini-thoracotomy. As 
percutaneous TAVI valves (Fig 4.H) have not stent, their hemodynamic performance 
and their durability are considered to be comparable with those of conventional stentless 
bioprostehsis. TAVI is currently reserved to patients with a predicted mortality, 
according to the euroSCORE, above 20%. A recent meta-analysis reporting on 3.519 
patients undergoing TAVI shows a 30-day mortality of 7.8%. 
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2.3 The problem of the patient prosthesis mismatch 
 
According to the original definition published by Rahimtoola in 1978 
21
, “mismatch can 
be considered to be present when the effective prosthetic valve area, after insertion into 
the patient, is less than that of a normal human valve.” This first subjective 
interpretation of mismatch was then replaced by using objective parameters able to 
detect how small has to be a prosthetic valve area to produce mismatch. There are two 
parameters used for the calculation of the prosthetic valve area: the effective orifice area 
(EOA) and the geometric orifice area (GOA). The EOA is the echocardiographic 
estimation of the flow area passing through the circular opening of the prosthesis itself. 
The GOA represents the inner area of the prosthesis, assumed to be circular and 
computed by the internal diameter of the prosthesis measured with a calliper. Dividing 
the EOA and the GOA for the body surface area, we obtain the indexed EOA (IEOA) 
and the indexed GOA (IGOA), which are currently used as reference parameters in 
mismatch analysis. 
Pibarot
22
, recently, has divided mismatch into 2 entities: severe mismatch defined by the 
presence of an indexed effective orifice area (IEOA) ≤0.65 cm2/m2 and moderate 
mismatch with IEOA value >0.65 and ≤0.85 cm2/m2. Severe patient-prosthesis 
mismatch (PPM) is a rare condition that has been reported to be an independent risk 
factor for overall 30-day mortality after aortic valve replacement (AVR)
23
. On the 
contrary, the question of whether the presence of moderate PPM does have an impact on 
post-operative survival is still open. In fact, since the introduction of its theoretical 
basis, the patient-prosthesis mismatch following aortic valve replacement has been the 
subject of a long debate. On one hand the persistence of post-operative trans-prosthesis 
gradients and the consequent delay of the left ventricular hypertrophy regression are 
13 
 
well documented in patients with mismatch
24
; on the other hand, its negative clinical 
impact is not widely recognized.  The simultaneous publication of two retrospective 
studies 
25
 
26
  reporting opposite conclusions about the impact of mismatch on mortality 
gives testimony of this controversy.  Contradictory outcomes regarding this issue could 
be due to the lack of methodological standardization in studies about patient-prosthesis 
mismatch.  A crucial point is the selection of the values for the EOA of the prosthetic 
valves.  It has been suggested by Rahimtoola
27
 that EOA values should be calculated 
from echocardiographic studies at 6 months in each patient undergoing aortic valve 
replacement. Many authors prefer not to use the EOA obtained by an early post-
operative echocardiography (fig. 5). In fact, the EOA is a physiological parameter that 
may vary with flow rate, cardiac output and ventricular function, which could jeopardise 
its assessment in the immediate postoperative period. For these reason, most of the 
studies analysing the mismatch use the EOA values derived from the literature. These 
values are obtained from echocardiographic studies carried out after the first semester in 
a sample of patients who underwent AVR. Thus, in the literature it is possible to find 
the mean EOA of any prosthesis and of any size (table 1).  Also, the use of literature-
derived mean effective orifice area values has been reported to have the highest 
sensitivity in predicting mismatch
28
. At the same time, the GOA data have low 
prediction sensitivity because of their tendency to overestimate the EOA.   
14 
 
 
Fig 5.The effective orifice area (EOA) of a bioprosthesis represents the flow area 
passing through the circular opening of the prosthesis itself. In an open position bileaflet 
mechanical prostheses show three elliptic flow areas. The sum of them represents the 
EOA of the mechanical prosthesis. From  Pibarot P, Dumesnil JG. Heart. 2006;92; 
1022-9. 
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Tab 1. Effective orifice area values published by Pibarot and Dumesnil. Rev Esp 
Cardiol, 2010;63(4):387-9 
 
 The residual transvalvular pressure gradient (PG) is the most commonly used indicator 
to assess the residual obstruction of the prosthesis and is exponentially correlated with 
the IEOA. The IEOA can be decreased within a wide range without significantly 
changing the PG until reaching a value of 0.85 cm
2
/m
2
, when a steep increase in PG 
occurs
29
. On the basis of this hemodynamic principle, it is widely accepted that PPM 
(IEOA ≤0.85 cm2/m2) should be avoided. Pibarot and Dumesnil 30 proposed a 3-step 
algorithm for its prevention, as follows: a) calculate the patient’s body surface area 
(BSA); b) determine the minimal valve EOA required to ensure an IEOA >0.85, >0.80, 
or >0.75 cm
2
/m
2, given the patient’s BSA as calculated in step 1; and c) select the type 
and size of prosthesis that has reference values for EOA greater than or equal to the 
minimal EOA value obtained in step 2.  
16 
 
Anyway there is not a unique definition of mismatch. Alternative in-vivo EOA cut-off 
values for definition of PPM are 0.90
31
, 0.80
32
, and 0.75 cm
2
/m
2
  
33
. The new European 
guidelines of heart valve disease
34
, published in 2012, confirm the cut-off value of 
severe mismatch proposed by Pibarot as they state that ”if the valve prosthesis– patient 
ratio is expected to be less than 0.65 cm
2
/m
2
, enlargement of the annulus to allow 
placement of a larger prosthesis may be considered”. 
Thus, in those patients with a large BSA and relatively small aortic annulus requiring 
AVR, the native annulus may not fit the size of the prosthesis required and so the 
surgeon faces the problem of whether to perform an annular enlargement procedure or 
to possibly compromise the surgical result by accepting PPM. A number of annular 
enlargement procedures have been described: the Nicks procedure
35
, the Manouguian 
technique 
36
 and the Konno procedure
37
. These techniques allow for the implantation of 
prosthetic valves 1 or 2 sizes larger than the original size of the aortic annulus
38
. 
Although these procedures have been frequently performed with good results, some 
authors have reported increased operative mortality
39
. 
It is clear that when performing these types of procedures, there is an increase in cross-
clamp time
40
. This variable has been suggested to be associated with increased mortality 
following AVR, particularly in the elderly
41
. The use of a stentless bioprosthesis has 
been proposed as an alternative to annulus enlargement when facing the possibility of 
PPM. This type of prosthesis has been said to have an excellent hemodynamic profile, 
and resembles native aortic valve function when assessed by transthoracic 
echocardiography (TTE) postoperatively
42
. Nevertheless, according to a recent meta-
analysis, the clinical significance of this hemodynamic advantage is not very clear
43
. 
Thus, it seems that neither annular enlargement nor stentless prostheses are a perfect 
solution to the problem of PPM. 
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2.4 Mismatch as risk factor for post-operative survival: a review of the literature 
 
As mismatch has been reported to increase mortality after aortic valve replacement, we 
carried out a literature search to identify the evidence supporting this hypothesis. 
 
2.4.1 Search methodology 
 
 We searched Medline, Embase and Cochrane Library for publications containing the 
words: aorta (OR aortic OR AVR OR aortic valve replacement) AND mismatch (OR 
mismatched OR mismatching OR patient-prosthesis mismatch OR PPM) AND 
mortality, updated to August 2013. Inclusion criteria were: studies analyzing the impact 
on mortality of PPM in adult patients (≥18 years) undergoing AVR. The denomination 
of mismatch had to be based on IEOA, IGOA or Z value. We included data from only 
the last publication of centers that had produced sequential reports. 
 
2.4.2 Search outcomes 
 
A total of 389 papers were identified using the reported search of which 22 represented 
the best evidence according to the Best Evidence Topics methodology (BETs)
44
.  
The BETs are generated as a result of clinical questions, which in this case was: is PPM 
an independent risk factor for mortality after aortic valve replacement? 
The BETs are developed through a review of Medline, Embase and Cochrane 
Library by a structured search strategy. The objective of the Best bets is to review the 
best available evidence by a “fast track” procedure. They are published regularly in 
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peer-reviewed journals (Emergency Medicine Journal, Archives of Disease in 
Childhood, Interactive Journal Cardiovascular and Thoracic Surgery). 
The following studies are the best evidence according to the Best Evidence Topics 
methodology. 
Bridges et al.
45
 analyzed 42,310 patients, to our knowledge the largest sample 
population. Prosthesis with small GOA or EOA were reported to be associated with 
increased early operative mortality, but among patients receiving the same model and 
size prosthesis, elevations in BSA were associated with a decrease rather than an 
increase in operative mortality. The authors concluded that in AVR, priority should be 
given to prosthesis durability, surgeon experience, technical ease and speed of 
implantation. Once these factors have been considered, they have accepted it may be 
reasonable to give preference to higher projected in vivo EOA or GOA prosthesis. 
Blackstone et al.
46
 reported that an indexed GOA ≤1.2 cm2/m2 increased 30-day 
mortality by 1–2%. However, the study was unable to identify mismatch as a predictor 
of late survival. It was speculated that the multifactorial nature of the reduced survival 
after AVR could have masked mismatch impact on long-term mortality.  
Blais et al.
47
 who, unlike the previous author, used IEOA instead of IGOA values, 
showed that both severe and moderate mismatch were independent predictors of short-
term mortality. Also, the impact of PPM on survival was maximum when it was severe 
and in patients with left ventricle dysfunction.  
Ruel et al.
48
 confirmed the importance of left ventricle dysfunction in patients with 
moderate mismatch, showing clearly that this subgroup of patients had a higher late 
mortality than patients with PPM and normal ejection fraction.  
19 
 
Kohsaka et al.
49
 and Tasca et al.
50
  analyzed patients with pure aortic valve stenosis 
reporting a higher late-term mortality of patients with moderate mismatch. Equally, 
Walther et al.
51
 were able to show that moderate mismatch was a predictor of adverse 
outcome after AVR. 
 Florath et al.
52
  and Mohty et al.
53
 showed independently that severe PPM, but not 
moderate PPM, was an independent risk factor for late mortality. Yap et al.
54
 confirmed 
that severe PPM was independently associated with higher early mortality.  
On the other hand, Mascherbauer et al.
55
, Fuster et al.
56
, Nozohoor et al.
57
, Moon et al. 
58
, Flameng et al.
59
, Frapier et al.
60
, Bové et al.
61
 and Rao et al.
62
, did not analyze 
separately the conditions of severe and moderate PPM. None of these studies was able 
to show that PPM was an independent predictor of either early or late survival after 
AVR. Monin et al.
63
 came to the same conclusions analyzing a sample population with 
low-gradient aortic stenosis. Milano et al.
64
 analyzed a sample population receiving 19- 
or 21-mm mechanical prostheses. According to this study, IEOA was not an 
independent predictor of early or late mortality, but it was a predictor of cardiac events. 
A lack of impact of PPM on late survival was also reported by Medallion et al.
65
, who 
used a multivariable hazard function to study risk factors for overall mortality after 
AVR.  
According to the study of Howell et al.
66
, and in contrast to the above mentioned study 
which focused on severe PPM, an IEOA <0.60 cm
2
/m
2
 did not affect either in-hospital 
mortality or late mortality. This finding could be explained by the fact that, as opposed 
to all other articles based on IEOA, this study used the in vitro EOA values and not the 
in vivo EOA values. In vitro EOA values have been shown to have a very low 
sensitivity to detect PPM 
67
 . 
20 
 
Table 1. Studies on mismatch selected according to Best Evidence Topics methodology. 
Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
Florath,
 
2008 
Germany 
Prospective 
cohort study 
[52] 
533 patients 
undergoing AVR. 
Mean age: 71.1 ± 9 
years. 
Exclusion criteria: 
not specified. 
52% 28% Not evaluated Severe PPM: Yes  (HR: 
1.9; 95% CI :1.08-3.21) 
Moderate PPM: No 
Moderate and severe PPM were studied separately. Severe mismatch  
but not moderate mismatch, was an independent  predictor of late 
mortality after adjustment for age, left ventricular ejection fraction, 
atrial fibrillation, NYHA class, serum creatinine, and hemoglobin 
level. Mean follow-up time:  4.7 ± 2.2 years. EOA was studied by 
echocardiography. 
Kohsaka, 2008  
U.S.A. 
Prospective 
cohort study  
[49] 
 
469 patients 
undergoing 
mechanical AVR for 
aortic stenosis. 
Mean age: 56.1±11.5 
years. 
Exclusion criteria: 
endocarditis, 
concomitant 
procedures other than 
CABG. 
39% 4%  
 
Not evaluated Yes (HR: 1.6; 95% CI 
:1.4-2.3) 
Moderate and severe PPM were grouped together. Predictors of 
mismatch included small aortic valve sizes (19 and 21 mm) (p<0.01), 
obesity (p<0.01), and age > 65 years (p<0.01). Mismatch was a 
significant predictor of poorer survival, even after adjustment for all 
significant clinical predictors of late mortality. Median follow-up 
time: 7.9 years (interquartile range: 5.0–10.0 years). EOA was 
derived from published reference values. 
Mascherbauer,
 
2008  
Austria 
Retrospective 
cohort study 
[55] 
361 patients 
undergoing AVR for 
aortic stenosis. 
Mean age: 69.4±9.3 
years. 
Exclusion criteria: 
aortic regurgitation.  
51.3% 3% No No 
Moderate and severe PPM were grouped together. Patients with PPM 
were older (p<0.0001), more often female (p<0.0001) more 
symptomatic (p =0.001), more often suffered from coronary artery 
disease, (p =0.04), triple vessel disease (p =0.03) and hypertension (p 
=0.01) and presented with a higher euroSCORE (p<0.0001).   
Mismatch was not an independent predictor of early or late survival. 
Median follow-up time: 4.1 ±2 years. EOA was derived from 
published values 
Bridges, 2007  
U.S.A 
Retrospective 
cohort study 
[44] 
 
42,310 patients 
undergoing isolated 
AVR. 
Mean age: 66.6 
±10.1 years. 
Exclusion criteria: 
double valve 
replacement, 
concomitant surgical 
Not 
evaluated 
Not 
evaluated 
Yes  Not evaluated 
PPM was studied mainly as a continuous variable.  Prostheses with 
small GOA or EOA area are associated with increased operative 
mortality. But among patients receiving the same manufacturer’s 
model and labeled size, increasing degrees of mismatch defined by 
decreasing the ratio of EOA/BSA or GOA/BSA are generally 
associated with better outcomes. For a patient with BSA = 2.0 m², a 
decrease in EOA from 2.00 cm² to 1.50 cm² is associated with 
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
procedures other than 
CABG, stentless 
valves implantation, 
active endocarditis 
increased mortality (OR: 1.35; 95% CI: 1.21-1.52). F-U time: within 
30 days from surgery.  EOA derived from published values. 
Fuster, 2007   
Spain 
Retrospective 
cohort study 
[56] 
 
743 patients 
undergoing AVR for 
predominant aortic 
valve stenosis. 
Mean age: 66.5±9.6 
years. 
Exclusion criteria: 
previous AVR, 
emergent surgery, 
endocarditis, any 
concomitant 
procedure.  
23.8% 3.9 % No No 
Moderate and severe PPM were grouped together. Mismatch 
increased early mortality only in the subgroup with high left ventricle 
mass index (p<0.05) and not the whole population. With regard to the 
late survival PPM was not an independent predictor of overall 
mortality, but it was an independent predictor of cardiac mortality 
(OR: 3.38, 95% CI: 1.37–8.31; p<0.01). Mean follow-up time: 
6.9±2.4 years. EOA was derived from published reference values 
Yap, 2007  
Australia 
Retrospective 
cohort study 
[54] 
 
 
701 patients 
undergoing AVR. 
 
Mean age: 70.7±10.3 
years. 
 Exclusion criteria: 
not specified 
 
Not 
evaluated 
6.6% Yes 
(OR: 6.07; 95% 
CI:1.66-22.16 
Not evaluated 
Study focused on severe PPM. Severe PPM was independently 
associated with higher early mortality. Severe mismatch was not 
associated with stroke, prolonged ventilation, new renal failure, 
prolonged post-operative stay, prolonged ICU stay or readmission 
within 30 days. Follow-up time: within 30 days of surgery. EOA was 
derived from published reference values. 
Nozohoor, 
2007  
Sweden 
Retrospective 
cohort study 
[57] 
1568 patients 
undergoing AVR. 
Mean age: 73.5 years 
Exclusion criteria: 
double valve 
replacement, 
concomitant surgical 
procedures other than 
CABG, stentless 
valves implantation, 
active endocarditis 
49.5% 3.8% No No 
Moderate and severe PPM were grouped together. According to 
multivariable analysis, PPM was not a predictor of early or late 
overall mortality. Mismatch was associated with an increased risk of 
postoperative neurological events (OR 2.26, 95% CI 1.05-4.83, p = 
0.037). Mean follow-up time: 4.3± 3.1 years. EOA was derived from 
published reference values. 
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
Monin, 2007 
France  
Prospective 
cohort study  
[63] 
 
139 patients with 
severe symptomatic 
aortic stenosis, mean 
transaortic pressure 
gradient <40 mm Hg, 
left ventricle ejection 
fraction ≤0.40% or 
cardiac index <3.0 
L/min/m². 
Exclusion criteria: 
severe extra cardiac 
comorbidities, more 
than mild aortic or 
mitral regurgitation, 
atrial fibrillation.  
5% 51.7% No No 
Moderate and severe PPM were grouped together. Neither label valve 
size, EOA or indexed EOA as continuous variables nor moderate–
severe PPM as dichotomous variable were predictive of early or late 
all-cause mortality.  Median follow-up time: 3.6 years (interquartile 
range: 2-5.6 years). Median age: 72. EO derived from published 
values 
Moon, 2006  
USA 
Retrospective 
cohort study 
[58] 
 
1,400 patients 
undergoing AVR 
 
Mean age: 67 ± 14 
years. 
Exclusion criteria: 
homograft and 
autograft 
implantation. EOA 
was derived from 
published reference 
values. 
 
37.7% Not 
evaluated 
No No 
Study focused on moderate PPM. Mismatch was not an independent 
risk factor for early mortality or late mortality for the whole 
population. Mismatch was associated with impaired late survival in 
the following subgroups:  patients <60 years old (p < 0.005),  patients 
with a BSA  1.7 to 2.1 m² receiving bioprosthetic (p < 0.05) and 
mechanical (p<0.005) valves and  patients with a BSA >2.1 m² 
receiving a mechanical prosthesis (p<0.04). Mean follow up time: 
3.7± 3.1 years. 
Ruel , 2006  
U.S.A 
Prospective 
cohort study  
[48] 
805 patients 
undergoing AVR. 
 
Mean age: 63.9±12.4 
years.  
Exclusion criteria: 
concomitant mitral 
valve surgery. EOA 
was derived from 
published reference 
values. 
40.3% Not 
evaluated 
Not evaluated No 
Study focused on moderate PPM. Mismatch was associated with 
impaired late survival only in the subgroup of patients with left 
ventricle ejection fraction < 50% (HR: 2.8 (95% CI, 1.1-8.0; p =0 
.03). Mean follow-up time: 5.5 ± 3.5 years.  
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
Flameng, 2006  
Belgium 
Retrospective 
cohort study 
[59] 
506 patients 
undergoing single 
AVR and receiving a 
CE Perimount 
bioprosthesis. 
Mean age: 73.3 
(range 57-87 years) 
Exclusion criteria: 
not specified 
20.1% 0.2% No No 
Moderate and severe PPM were grouped together. According to 
multivariable analysis moderate mismatch was not an independent 
predictor of early mortality or late mortality. Mean follow-up time: 
6.1±4.8 years. EOA values were derived from projection of EOA 
measured by echocardiography in 122 patients. 
Mohty, 2006  
U.S.A 
Prospective 
cohort study  
[53] 
 
388 patients 
receiving a 19- or 21-
mm standard or 
Hemodynamic Plus 
(HP) SJM bileaflet 
mechanical 
prosthesis. 
Mean age: 62.0± 13 
years 
Exclusion criteria: 
peri-operative death, 
or if a postoperative 
echocardiogram was 
not performed at the 
Author’s  Institution 
within 1 year after 
AVR. 
43.3% 17.0% Not evaluated Severe PPM: Yes  (HR: 
2.18; 95% CI: 1.24- 
3.85) 
Moderate PPM: No 
Moderate and severe PPM were studied separately. According to 
multivariable analysis severe mismatch, but not moderate mismatch, 
was an independent predictor of late overall mortality. Mean follow-
up time: 5.3±3.3 years. EOA assessed by transthoracic 
echocardiographic study performed at Author’s institution. 
Tasca, 2006  
Italy 
Prospective 
cohort study  
[50] 
315 patients with 
pure aortic stenosis. 
Mean age: 70.8±9.5 
years 
Exclusion criteria: 
not specified. 
 
42.0% 5.0% Not evaluated Yes (HR: 4.2; 95% CI: 
1.6-11.3) 
Moderate and severe PPM were grouped together. According to 
multivariable analysis mismatch was an independent predictor of 
overall late mortality and of cardiac events: cardiac death, sudden 
death, heart failure, syncope/lipothymia, angina (HR: 3.2; 95% CI: 
1.5-6.8). Mean follow-up time: 3.7±1.7 years. EOA was derived from 
published reference except from Mitroflow.  For this prosthesis, the 
EOA values were obtained by echocardiography an then they were 
projected to patients receiving it. 
Bové, 2006  
Belgium. 
Retrospective 
cohort study 
[61] 
255 patients 
undergoing AVR 
receiving 
bioprosthesis.     
Mean age: 75.8±6.7 
years  
27.9% 1.2% No No 
Moderate and severe PPM were grouped together. Mismatch was a 
predictor of late overall mortality according to bivariable analysis, 
but not according to multivariable analysis. Mean follow-up time: 4.3 
years (range 1-11.3 years). EOA was derived from published 
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
 Exclusion criteria: 
pure aortic 
regurgitation, 
endocarditis. 
reference values. 
Walther,  2006 
Germany 
Prospective 
cohort study  
[55] 
 
4,131 patients 
undergoing AVR. 
Mean age: 66.2±9.2 
years 
Exclusion criteria: 
implant of stentless 
aortic prosthesis. 
EOA was derived 
from published 
reference values. 
 
26.7% 2.3% Yes (Odds Ratio 
no provided) 
Yes (OR: 1.37; 95% CI 
1.1 - 1.8) 
Moderate and severe PPM were grouped together. According to 
multivariable analysis mismatch was a predictor of adverse outcome 
after AVR, together with age > 70 years (p = 0.002), emergency 
indication (p < 0.001), EuroSCORE > 10 (p < 0.001), and 
requirement for additional procedures (p < 0.001). Mean follow-up: 
5.2 ± 3.5 years. 
Howell, 2006   
UK 
Prospective 
cohort study  
[66] 
 
1,418 patients 
undergoing AVR. 
Mean age: 65.5 
±12.6 
Exclusion criteria: 
procedures other than 
CABG, pre-existing 
valve prosthesis 
other than aortic 
valve, active 
endocarditis. 
 
Not 
evaluated 
10.6% No No 
Study focused on severe PPM. PPM did not affect in-hospital 
mortality neither in the whole sample nor in the subgroup with 
ejection fraction < 30%. Also PPM did not affect late survival neither 
in the whole sample population nor in the subgroup with pure aortic 
stenosis. Median follow-up time: 3 years (interquartile range 1.5—
3.7 years). EOA was derived from manufacturers’ in vitro data; GOA 
was calculated from the manufacturers’geometric internal valve 
orifice diameter. 
Blackstone, 
2003  U.S.A 
Prospective 
cohort study  
[46] 
 
13,258 undergoing 
AVR 
Mean age: 64.6 
±11.8.         
Exclusion criteria: 
preexisting valve 
prosthesis in a 
location other than 
aortic, endocarditis, 
emergency, 
concomitant 
procedures other than 
CABG.  
Not 
evaluated 
Not 
evaluated 
Yes  
 
No 
PPM was studied as a continuous variable. An IGOA values <1.2 
cm²/m² was an independent predictor of early mortality. IGOA < 1.2 
cm²/m² or  standardized orifice size <-2.5  was associated with a 1% 
to 2% increase in 30-day mortality- After adjustment or balancing 
score an IGOA values < 1.1 cm²/m² was not an independent predictor 
of  intermediate-term  or long-term  survival. Mean follow-up: mean 
5.3 ± 4.7 years. GOA was calculated from the manufacturers’ 
geometric internal valve orifice diameter. 
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
Blais,  2003    
Canada 
Prospective 
cohort study  
[51] 
 
1,266 patients 
undergoing AVR. 
Mean age 69.7±8.5 
years 
Exclusion criteria: no 
specified 
 
36% 2% Yes Not evaluated 
Moderate and severe PPM were studied separately. In multivariable 
analysis severe and moderate mismatch were independent predictors 
of early mortality: moderate PPM HR 2.0; 95% CI: 1.1 – 3; severe 
PPM HR 12.6 95% CI: 4.3 - 37.0. For every category of PPM, the 
risk of mortality was greater in patients with a preoperative left 
ventricular ejection fraction <40%. Follow-up time: within 30 days 
after operation. EOA was derived from published reference values. 
Milano, 2002  
Italy 
Retrospective 
cohort study  
[64] 
 
229 patients 
undergoing AVR 
(with or without 
CABG) for aortic 
stenosis with  19 or 
21 mm Jude Medical 
standard prosthesis.  
Mean age 63.7 ±12.5  
Exclusion criteria: 
More than mild 
aortic regurgitation, 
concomitant mitral or 
tricuspid valve 
operations. 
73.2% 8.1% No No 
IEOA studied as continuous and dichotomic variable. According to 
multivariable analysis IEOA was not an independent predictor of 
early mortality, late mortality, valve related complications, and valve 
related death. But IEOA at discharge was an independent predictor (p 
= 0.007) of cardiac events (new episodes of angina, myocardial 
infarction, congestive heart failure, and ventricular arrhythmia 
requiring hospitalization or leading to death).  Mean follow-up time: 
8 ± 5 years. EOA values were obtained by echocardiography. 
Frapier, 2002  
France 
Retrospective 
cohort study 
 [60] 
90 patients 
undergoing AVR 
with Medtronic 
Intact valve. 
Mean age 72.6 ± 7.9 
years 
Exclusion criteria: 
not specified. 
71.1% Not 
evaluated 
Not 
evaluated 
No 
Study focused on moderate PPM. According to multivariable analysis 
mismatch was not an independent predictor of late overall mortality 
or cardiac mortality. Mean follow-up time: 6.6 years. EOA derived 
from published values. 
Rao, 2000  
Canada 
Retrospective 
cohort study  
[62] 
 
2,154 patients 
undergoing isolated 
AVR with or without 
concomitant CABG 
Mean age 66.1  ± 1.9 
years  
Exclusion criteria: 
not specified. 
  
Not 
evaluated 
10.5% No No 
Study focused on moderate PPM. According to multivariable analysis 
mismatch was not an independent predictor of early or late overall 
mortality. But prosthesis mismatch was an independent predictor of 
valve-related mortality (RR 1.46, 95% CI 0.95 to 2.24). Mean follow-
up time: 6.2 ±4.1 years. EOA were obtained from the manufacturer’s 
specifications 
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Author, date 
and country, 
Study type 
(level of 
Evidence) 
Patient group PPM prevalence PPM as risk factor for mortality 
Moderate Severe Early  Late 
Medallion, 
2000  
USA 
Retrospective 
cohort study  
[65] 
 
892 patients 
undergoing AVR for 
aortic stenosis (with 
or without 
regurgitation) 
Mean age:64.1±12.1 
Exclusion criteria: no 
concomitant 
procedures, such as 
CABG, previous 
cardiac surgery. 
GOA were obtained 
from the 
manufacturer’s 
specifications 
 
Not 
evaluated 
Not 
evaluated 
Not evaluated No 
PPM was studied as a continue variable. There were too few in-
hospital deaths to allow a meaningful examination of early risk 
factors. According to the hazard function no valve type or expression 
of valve size were identified as a risk factors for overall mortality in 
the constant or late phases after AVR. Mean follow-up time: 5.0 ± 
3.9 years.  
Table1. AVR: Aortic valve replacement. IEOA: indexed effective orifice area; IGOA: indexed 
geometric orifice area; PPM: patient-prosthesis mismatch 
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2.5 Mismatch as risk factor for structural valve deterioration 
 
One of the more active groups in mismatch analysis is the Leuven University which 
published the first report in 2006
53
 analysing 506 patients undergoing AVR with a 
bioprosthesis. As above mentioned, in this initial study Flameng failed to show that 
PPM has an impact on post-operative survival. In 2010 the same group published a new 
report
68
, analysing a sample population of 564 patients undergoing AVR with a 
bioprosthesis. This study reported, for the first time in the literature, that PPM increases 
independently the risk of structural valve deterioration (SVD) of biological aortic 
prosthesis. These data were confirmed by a third report published by the same group in 
2013
69
. 
The SVD is the expression of intrinsic changes of a biological prosthesis, being the 
more frequent leaflet calcifications and leaflets tears. These intrinsic changes, producing 
potentially prosthesis stenosis or regurgitation, are the main determinant of the 
longevity of the bioprosthesis. A meta-analysis comprising 5,837 patients with porcine 
bioprostheses in aortic position published in 2001
70
  showed the SVD begins at 8 years 
from AVR. According to the current literature, the age of the patient at the time of AVR 
is the most important determinant of SVD, being this event more frequent in patients 
who underwent surgery < 65 years old
71
.  
Patients with chronic renal failure or with dialysis present a more rapid rate of 
progression of native aortic valve stenosis and could present a potentially accelerated 
SVD
72
. This association could be explained by the altered calcium metabolism observed 
in patients with chronic renal failure with hypercalcemia and abnormalities of mineral 
metabolism. In this regard, it is well known that enhanced plasma levels of Fibroblast 
growth factor-23, parathormone, phosphate and decreased levels of vitamin D, may 
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promote vascular damage and calcification
73
. Anyway, there is no evidence suggesting 
that in patients with dialysis the SVD has an impact on post-operative survival. For this 
reason the last European guidelines for the management of patients with valvular heart 
disease 
28, suggest that:” although SVD is accelerated in chronic renal failure, poor 
long-term survival with either type of prosthesis or an increased risk of complications 
with mechanical valves may favor the choice of a bioprosthesis in this situation”. 
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2.6 Clinical summary 
 
According to the current literature, patient prosthesis mismatch is a condition defined by 
an indexed effective orifice area ≤ 0.85 cm2/m2. To obtain the indexed orifice area, the 
EOA of the implanted prosthesis is divided for the body surface area of the patient. As 
previously mentioned the EOA can be obtained by published literature values or by a 
post-operative echocardiographic study. The former technique is the most common 
procedure of IEOA calculation in the current literature, basically because it is easy, it 
allows computing the pre-operative projection of the IEOA, and it has the highest 
sensitivity in predicting mismatch. Mismatch can be divided in two clinical entities: 
moderate mismatch (IEOA ≤0.85 cm2/m2 and >0.65 cm2/m2) and severe mismatch 
(IEOA ≤0.65 cm2/m2).  
Moderate mismatch is a quite frequent clinical entity; it is present in up to 40% of 
patients who underwent AVR. Up to now moderate PPM has not been clearly 
demonstrated  to increase the post-operative early or late mortality after aortic valve 
replacement, unless the patient presents with left ventricle dysfunction. In any case 
moderate mismatch can be associated with higher post operative trans-prosthetic 
gradient compared with patients without moderate mismatch.  
Severe PPM is a rare entity; it is present in about 3% of the population who underwent 
AVR.  Severe mismatch is an independent risk factor for early and late mortality after 
aortic valve replacement. Persistence of high trans-prosthesis gradients and lack of left 
ventricle mass regression are often observed in patients with severe PPM. For this 
reason the new European guidelines of heart valve disease 
28
, published in 2012, suggest 
that if the valve prosthesis– patient ratio is expected to be ≤0.65 cm2/m2, enlargement of 
the annulus to allow placement of a larger prosthesis may be considered. The 
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appropriate choice of the valve prosthesis is fundamental to get the maximal possible 
IEAO and to avoid, in most cases, severe PPM. Alternatively, there are different 
surgical techniques of aortic annulus enlargement which can be used to implant a larger 
prosthesis than that one which would fit anatomically. However, these techniques have 
a higher operative risk than the standard aortic valve replacement procedure.  
Recently PPM, defined as IEOA ≤0.85 cm2/m2, has been reported by the Leuven 
University, to be associated with the SVD of the bioprosthesis. Because the SVD is a 
complex process whose determinants are still to be clearly identified, the possibility that 
mismatch has a negative impact on SVD represents, in our opinion, a very interesting 
hypothesis to be tested also in our population. 
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Recapitulación 
Según la literatura actual, el desajuste paciente-prótesis es definido por un área efectiva 
de orifico indexado (AEOI) ≤ 0,85 cm2/m2. Para calcular el AEOI es necesario dividir el 
área efectiva de orificio (AEO) de la prótesis implantada por la el área de la superficie 
corporal del paciente. El AEO puede obtenerse a partir de artículos publicados en 
la literatura o de estudios ecocardiográficos realizados en el mismo paciente. La primera 
forma de calcular el AEO es la más utilizada, porque es más fácil, porque permite 
calcular en fase preoperatoria el AEOI para cada prótesis a implantar y porque el AEO 
así calculado presenta mayor sensibilidad en la predicción del desajuste.  
     El desajuste paciente-prótesis se puede dividir en dos entidades clínicas: moderado 
(AEOI ≤ 0,85 cm2/m2 y > 0,65 cm2/m2) y severo (AEOI ≤ 0,65 cm2/m2). El desajuste 
paciente-prótesis moderado es una entidad clínica relativamente frecuente y es 
diagnosticado hasta en el 40% de los pacientes intervenidos de recambio valvular 
aórtico (RVA). Hasta la fecha, no se ha demostrado de forma inequívoca que el 
desajuste moderado aumente la mortalidad post-operatoria, menos en el grupo de 
pacientes con disfunción ventricular izquierda. De todas formas, los pacientes con 
desajuste moderado presentan gradientes trans-protésicos más altos de los pacientes sin 
desajuste.  
     El desajuste paciente-prótesis severo es una entidad clínica poco frecuente, estando 
presente en el 3% de los pacientes intervenidos de RVA. El desajuste severo es un 
factor de riesgo para mortalidad a corto y a largo plazo después de un RVA. En este 
sentido, la persistencia de gradientes trans-protésicos altos y la falta de regresión de la 
hipertrofia del ventrículo izquierdo están presentes frecuentemente en los pacientes con 
desajuste severo.     Por esta razón, la nuevas guías europeas sobre la patología valvular 
cardiaca, sugieren considerar la posibilidad de realizar una ampliación de la raíz aortica 
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en los pacientes cuyo AEOI calculado previamente a la cirugía sea ≤0,65 cm2/m2. De 
hecho, existen distintas técnicas quirúrgicas que permiten ampliar la raíz aórtica para 
implantar una prótesis que sea al menos una medida superior a la que cabría 
anatómicamente. De todas formas, estos procedimientos presentan un riesgo operatorio 
más alto  que el RVA estándar. Recientemente la Universidad de Leuven ha demostrado 
que el desajuste paciente-prótesis, definido por un AEOI ≤0,85 cm2/m2 se asocia a un 
aumento de la tasa de degeneración estructural de las bioprótesis aórtica. Dado que la 
degeneración estructural protésica es un evento complejo cuyos determinantes no han 
sido aclarados del todo, la posibilidad que el desajuste paciente-prótesis pueda de 
alguna forma tener un impacto sobre este fenómeno, es una hipótesis muy interesante 
que queremos comprobar en nuestra población. 
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3. Hypothesis 
 
All biological substitutes of heart valves undergo a process of structural valve 
deterioration (SVD), which represents the main determinant of their longevity. It has 
been reported that patient-prosthesis mismatch can increase the SVD process in patients 
receiving a bioprosthesis in aortic position
62
. 
In the present study we will test the following hypotheses: 
1. Patient-prosthesis mismatch increases independently the risk of undergoing 
reoperation because of SVD in a Spanish population.  
2. Patient-prosthesis mismatch increases independently 30-day and mid-term 
mortality after aortic valve replacement. 
3. Different PPM degrees could have different impacts on post-operative mortality 
and on reoperation because of SVD. 
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4. Objectives 
 
In a sample population of 387 consecutive adult patients who underwent aortic valve 
replacement with a biological prosthesis in the Fundación Jiménez Díaz from 1974 to 
2009, we will analyze: 
1. The incidence of patient-prosthesis mismatch in a Spanish population. 
2. The impact of different patient-prosthesis mismatch degrees on post-operative 
mortality. 
3. The impact of different patient-prosthesis mismatch degrees on reoperation 
because of SVD. 
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5. Materials and methods 
 
In total, 387 consecutive adult patients who underwent aortic valve replacement with a 
bioprosthesis from 1974 to 2009 at the Fundación Jiménez Díaz were retrospectively 
reviewed.  Follow-up information was obtained from the electronic database of the 
Cardiac Surgery Department. Patients status during follow-up was determined by 
hospital visit carried out on a yearly basis. Our database did not include 
echocardiographic data. Echocardiograms files were not recorded as electronic files 
before the year 2000. After this year, echocardiograms were electronically recorded and 
obtained routinely before discharge and periodically (generally yearly), and thereafter at 
the discretion of referring physicians. We were not able to find echocardiographic data 
of the 286 patients (74% of the whole sample population) who underwent surgery from 
1974 to 1986. This important volume of missing data forced us to focus the study on the 
incidence of reoperation due to SVD instead of focusing on incidence of SVD itself. 
The study was approved by the Local Ethics Committee. 
A median sternotomy was performed via a standard approach, with cardiopulmonary 
bypass and mild systemic hypothermia (32ºC) being used in all patients. 
Myocardial protection was achieved with a combination of antegrade intermittent cold 
blood o crystalloid cardioplegia and topical cooling.  The prosthesis size was selected 
according to the size of the aortic annulus, as determined by the manufacturer’s 
instructions. The largest suitable valve was always selected for any given patient. 
Valvular prostheses were implanted in the supra-annular position with mattress sutures, 
using Teflon pledgets. 
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5.1 Definitions 
 
The patient’s BSA was derived using the Dubois formula. The in-vivo EOA values 
were estimated by reference tables based on mean EOA values of the different 
prosthesis, type and size 
74
 
75
 .  
EOA published values of the Hancock  standard  were  heterogeneous and sometimes 
even larger than those of the Hancock II (modified orifice) 
76
 
77
. For this reason we 
decided to be conservative and apply for the Hancock standard the same EOA values of 
the Hancock II, published by Pibarot et al. 
The indexed effective orifice area (IEOA) was obtained by dividing the estimated EOA 
by the patient’s BSA. Our mismatch analysis was focused on IEOA studied as 
continuous variable and as categorical variable. In particular we used three cut-off 
values: IEOA ≤0.85cm2/m2, IEOA ≤0.70cm2/m2 and IEOA ≤0.65cm2/m2. 
Structural Valve Deterioration (SVD) was defined, according to the current guidelines 
for reporting mortality and morbidity in cardiac surgery
78
, as “changes intrinsic to the 
valve, such as wear, fracture, poppet escape, calcification, leaflet tear, stent creep, and 
suture line disruption of components of a prosthetic valve”. 
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5.2 Indications for bioprosthesis replacement 
 
The first indication to replace the bioprosthesis was the presence of severe stenosis 
(mean trans-prosthesis gradient >50 mmHg) or regurgitation (3 or 4 out of 4) associated 
with heart failure symptoms or syncope. The second indication was a diagnosis of 
endocarditis. In all cases, diagnosis of SVD was carried out by the operating surgeons 
through macroscopic evaluation of the bioprosthesis according to two parameters: 
calcification: none (no calcification at all), mild (partial calcification of 1or 2 leaflets), 
moderate (partial calcification of the three leaflets), severe (complete calcification of the 
three leaflets), and leaflet tears (present/absent). 
 
5.3 Statistical analysis 
 
Continuous variables were expressed as median plus range, or mean ± standard 
deviation. Dichotomous categorical variables were indicated as absolute frequency 
(percentage). As a first step, all continuous data listed in table 1 were analyzed, one by 
one, by Student’s t-test for independent samples or Mann-Whitney U-test, when 
appropriate. Categorical data were analyzed  by chi-square test, or Fisher’s exact test 
when appropriate to identify univariable predictors of 30-day mortality. Any variable  
with a p-value ≤0.10 in the univariate analysis was entered into a backward 
multivariable logistic regression model. From this model, independent predictors of 30-
day mortality were obtained. As a second step, a standard single predictor and 
multivariable (p< 0.10= threshold to enter the variable in the model) Cox regression 
analysis was carried out to identify independent predictors of long-term mortality. 
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All data listed in table 2, were entered, one by one, in a Cox regression univariable 
model inserting “bioprosthesis replacement for SVD” as dependent variable. Any 
variable with a p-value ≤0.10 in the univariable analysis was entered into a backward 
multivariable Cox regression model (p >0.10 = threshold to remove the variable from 
the model). From this model the independent predictors of aortic bioprosthesis 
replacement for SVD of the whole sample population were obtained. 
A propensity score was computed and used to reduce the selection bias related to the 
retrospective nature of this study. This was defined as the conditional probability of 
belonging to the PPM group versus the control group given the covariates. Hence, the 
propensity score was used to balance the differences on observed covariates between the 
two groups by a multivariable adjustment
79
. In other words, this analysis decreases the 
probability that differences in terms of incidence of aortic bioprosthesis replacement 
were due to differences of comorbidities between patients with mismatch and patients 
without mismatch. 
Thus, all operative data listed in Table 2 predictive of group membership (p value 
≤0.15) were entered into a logistic multivariable regression model with mismatch (1 = 
PPM group; 0 = control group) as the dependent variable. The variables used for the 
propensity score computation were: age, body surface area, body mass index, left 
ventricle ejection fraction, type of aortic lesion, clamp time, concomitant CABG, model 
bioprosthesis and type of bioprosthesis. The final model had an area under the receiver 
operating characteristic curve of 0.89. 
 
39 
 
Propensity score
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
Se
ns
it
iv
it
y
 
Receiver Operating Characteristic (ROC) curves plotting the propensity score against the 
variable “group membership”. Area under the curve: 0.89  
As described in table 2, our sample population underwent surgery trough a 35 years 
long period (from 1974 to 2009). Because we cannot exclude that the variable “year of 
surgery” could have an impact in procedural details which could influence the rate of 
SVD over the years, we decided to use this variable in the analysis. In particular we 
transform the variable “year of surgery” in a dichotomic one: we assigned the value 1 to 
the dates ranging from 1974 to 1991, and the values zero to the dates ranging from 
1992-2009. Then we forced this variable in the Cox regression model for calculation of 
predictors of reoperation because of SVD. 
Unadjusted long-term survival and long term rates of freedom from aortic bioprosthesis 
replacement were calculated using the Kaplan-Meier method. The log-rank test was 
used to compare the curves of freedom from aortic bioprosthesis replacement for SVD 
of the two groups (PPM and control). The hazard ratio (HR) and the odds ratio (OR) 
values are shown with 95% confidence intervals (CIs). Proportional hazard assumption 
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was evaluated using the test based on the Schoenfeld residuals. The area under the curve 
(AUC) was used to measure how the regression logistic model predicted the outcome 
“30-day mortality”. Statistical analyses were performed using the 2012 R statistics 
package (www.r-project.org). MedCalc for Windows (version 9.3.7.0; MedCalc 
Software, Mariakerke, Belgium) was used for graphics. 
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6. Results 
 
Patients’ characteristics are listed in Table 2.  
 
 
Total 
(n=387) 
IEOA≤0.70cm2/m2 
(n=47) 
Control Group 
(n=340) 
*p  value   
Clinical data     
  Age  57.9±19.1 65.1±19.1 56.9±18.9 0.06 
  Female 118 (30.5%) 14 (29.8%) 104 (30.6%) 1 
  BSA (m²)*  1.70 ±0.17 1.9±1.3 1.7±0.17 <0.0001 
  BMI   23.9±3.9 27.4±3.8 23.5±3.7 <0.0001 
  IEOA 0.8±0.1 0.65±0.03 0.83±0.01 <0.0001 
  AF 26 (6.7%) 1 (2.1%) 25 (7.4%) 0.3 
  LVEF 55.3±12.1 61.0±10.6 54.5±12.1 <0.0001 
  NYHA III/IV 311 (80.4%) 39 (83%) 272 (80%) 0.8 
     
Type of aortic valve   lesion:    0.04 
Aortic  stenosis 177 (45.6%) 32 (68.1%) 144 (42.4%)  
Aortic regurgitation  159 (41.2%) 12 (25.5%) 147 (43.2%)  
Double lesion 51 (13.2%) 3 (6.4%) 48 (14.1%) 
 
 
Ethiology:    0.2 
 Rheumatic 295 (76.2%) 35 (74.5%) 260 (76.5%)  
 Degenerative calcific 64 (16.5%) 11 (23.4%) 53 (15.6%)  
 Endocarditis 28 (7.2%) 1 (2.1%) 27 (2.9%)  
     
Operative data     
REDO 27 (7.0%) 3 (6.4%) 24 (7.1%) 1 
Urgency 17 (4.4%) 2 (4.3%) 15 (4.4%) 0.9 
Clamp time 51.5±23.8 61.6±24.3 49.8±23.4 0.001 
Concomitant CABG 37 (9.6%) 10 (21.3%) 27 (7.9%) 
 
0.07 
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Total 
(n=387) 
IEOA≤0.70cm2/m2 
(n=47) 
Control Group 
(n=340) 
*p  value   
 
Model of Bioprosthesis 
    
Patients’ Age 
(<0.0001) 
Hancock (porcine; 
implantation years 1974-
1982) 
221 (57.1%) 14 (29.8%) 207 (60.9%) Mean age: 45.1±14.6 
(years) 
Hancock II (porcine; 
implantation years 1983-
2003 ) 
45 (11.6%) 8 (17%) 37 (10.9%) Mean age: 72.0±9.1 
(years) 
Carpentier Edwards supra-
annular (porcine; 
implantation years 1983-
1989) 
20 (5.2) 0 (0%) 20 (5.9%) Mean age: 77.6±5.0 
(years) 
Carpentier Edwards  
Perimount (bovine; 
implantation years 2001-
2007) 
97 (25.1%) 24 (51.1%) 73 (21.5%) Mean age: 68.3±8.2 
(years) 
Carpentier Edwards Magna 
(bovine;  implantation years  
2006-2009) 
4 (1)% 1 (2.1%) 3 (0.9%) Mean age: 76.5±2.6 
(years) 
     
Type of Bioprosthesis    <0.0001 
Bovine 101 (26.1%) 25 (53.2%) 76 (22.4%)  
Porcine 286  (73.9%) 22 (46.8%) 264 (77.6%)  
Table 2. Patients’ characteristics. AF: atrial fibrillation; BSA: Body surface area; CABG: coronary artery; 
IEOA: indexed effective orifice area; bypass grafting; LVEF: left ventricle ejection fraction; NYHA: 
New York Heart Association Class.  REDO: previous operation.  
*P values computed by uni-variate analysis. 
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The mean value of the IEOA was 0.81 ± 0.11 cm
2
/m
2
. 
Comulative frequency distribution of the IEOA
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Fig 1A. Cumulative frequency distribution of the IEOA values. 
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Fig 1B. Normal plot of the observed IEOA values (horizontal axis) and the z-scores of 
the observed IEOA. (Z-score =(x-mean)/SD). 
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The median follow-up period was 7.2 years (range: 0.5-22.5 years). Thirteen patients 
were lost to the follow-up, which was 97% complete. 
Of the whole sample population, 66.7% (n=258) presented with IEOA ≤0.85 cm2/m2, 
12.1% (47) had an IEOA ≤0.70 cm2/m2 and 5.2% (n=20) showed an IEOA ≤0.65 
cm
2
/m
2
.
 
Thirty day mortality was 6.5% (total deaths=25). Multivariable logistic regression 
analysis revealed four risk factors of early mortality: urgency surgery, redo surgery, 
female sex and patients’ age (table 3). The Area under the curve of the whole model 
was 0.74 (fig 2). IEOA was not an independent risk factor for 30-day mortality neither 
analyzed as continuous variable nor as categorical variable (IEOA ≤0.85cm2/m2, IEOA 
≤0.70cm2/m2 and IEOA ≤0.65cm2/m2). 
 
Variable OR Error 95% CI P value 
Age   1.026 0.0143                       1.000 -1.057    0.0494 
Urgency 5.811    4.1558     1.288 -22.491     0.0240   
Redo Surgery   4.436    2.5222     1.352- 12.994     0.0159 
Female sex         2.647    1.2552     1.051 -6.894   0.0389 
Table 3. Independent predictors of 30-day mortality 
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Fig 2. Receiver Operating Characteristic (ROC) curve showing the sensitivity of the 
multivariable model to predict the 30-day mortality. Area under the curve: 0.74.  
 
Of the 30-day survivors (n=362), 13 were lost at the follow-up. Among the remaining 
349 patients, 85 deaths were recorded, of which only 34 (40%) were cardiac events, and 
111 patients underwent reoperation for replacement of the aortic bioprosthesis. The 
median survival time of these 349 patients was 20.4 years. According to Kaplan Meier 
analysis ten years survival of the whole sample population was 74.4 ± 2.8 %. According 
to multivariable Cox regression analysis, there were four independent predictors of long 
term mortality. Female sex and left ventricle ejection fraction (LVEF) were identified as 
protector factors: female patients and patients with higher LVEF had a lower risk of late 
mortality compared with male patients and patients with lower LVEF. Patients’ age and 
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urgency surgery were identified as risk factors (table 4). IEOA was not an independent 
risk factor for long-term mortality neither analyzed as continuous variable nor as 
categorical variable (IEOA ≤0.85cm2/m2, IEOA ≤0.70cm2/m2 and IEOA ≤0.65cm2/m2). 
Variable HR Error 95% CI P value 
Age 1.032    0.0074     1.017-1.046     <0.0001 
Female sex             0.568    0.1619     0.324 -0.993     0.0383 
Ejection Fraction      0.980    0.0092     0.962- 0.998     0.0297 
Urgency 3.805    1.4243     1.827-7.925     0.0019 
Table 4. Independent predictors of long-term mortality 
  
Ten year freedom from reoperation for aortic bioprosthesis reoperation was 74.3±3.2%. 
Causes of aortic bioprosthesis reoperation were structural valve deterioration of the 
bioprosthesis (n=96), paravalvular leak (n=10) and acute endocarditis (n=5).  Of the 96 
explanted bioprostheses because of SVD, 93 were Hancock I, 1 was Hancock II and 2 
were porcine Carpentier Edwards.  According to unadjusted Kaplan-Meier analysis 
(figure 3 A, B, C), only patients with IEOA ≤0.70 cm2/m2 (but not patients with IEOA≤ 
0.85 cm
2
/m
2, nor  patients with IEOA ≤0.65 cm2/m2) had a higher incidence of 
reoperation because of structural valve deterioration when compared with that one of 
patients without mismatch (log-rank “p” value= 0.05).  
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Number at risk
Group: Patients with IEOA >0.70 cm2/m2
306 203 108 39 9 0
Group: Patients with IEOA ≤ 0.70 cm2/m2
43 19 4 1 1 0
Patients with IEOA >0.70 cm2/m2
Patients with IEOA ≤ 0.70 cm2/m2
Logrank test: p= 0.05
 
Figure 2A. Kaplan-Meier analysis of freedom from reoperation because of structural 
valve deterioration (SVD).  Patients with IEOA ≤ 0.70 cm2/m2 were reoperated less 
often than those with IEOA >0.70 cm
2
/m
2
 (p=0.05). 
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Figure 2B. Kaplan-Meier analysis of freedom from reoperation because of structural 
valve deterioration (SVD). Patients with IEOA ≤0.85 cm2/m2 do not show any 
difference in term of rate of reoperation when compared with patients with IEOA >0.85 
cm
2
/m
2
. 
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Figure 2C. Kaplan-Meier analysis of freedom from reoperation because of structural 
valve deterioration (SVD). Patients with IEOA ≤0.65 cm2/m2 do not show any 
difference in term of rate of reoperation when compared with patients with  IEOA >0.65 
cm
2
/m
2
. 
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This result was confirmed by the multivariable Cox regression analysis which identified 
two independent predictors of reoperation because of SVD: patients’ age and IEOA 
≤0.70 cm2/m2 (table 5).  These results did not change significantly after forcing into the 
model the variable “year of surgery”. 
After adjusting for propensity score, “patients’ age” maintained its statistical 
significance, while the variable “IEOA ≤0.70 cm2/m2” kept showing a hazard ratio of 2, 
with a statistical value just above the limit of statistical significance (p= 0.063). 
 
Variable HR Error 95% CI P value 
IEOA ≤0.70 cm2/m2 2.161 0.355 1.079-4.329 0.030 
Age 0.967    0.007 0.954-0.981      <0.0001 
     
After forcing into the 
model the variable 
“year of surgery” 
    
IEOA ≤0.70 cm2/m2 2.268 0.354 1.1362-4.529 0.02 
Age 0.970    0.007 0.956-0.984      <0.0001 
     
After Propensity 
score adjustment 
    
IEOA ≤0.70 cm2/m2 2.033 0.382 0.962-4.295 0.063  
Age 0.967 0.007 0.953-0.981 <0.0001 
Table 5. Independent predictors of reoperation because of structural valve deterioration. 
IEOA: indexed effective orifice area. 
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According to our multivariable analysis, the variables IEOA ≤0.65 cm2/m2 (p value: 
0.13), 
  
 IEOA ≤0.85 cm2/m2 (p value: 0.86),   and IEOA used as continuous variable (p 
value: 0.24), were not independent predictors of reoperation because of structural valve 
deterioration (SVD). 
 
Surgical records on explanted degenerated bioprostheses were obtained in 95 cases over 
96. Explanted bioprostheses were analyzed according to three parameters: prevalent 
lesion (based on echocardiographic records) presence of leaflet tear and presence of 
calcification (based on surgical records). Bioprostheses explanted from patients with 
IEOA ≤0.70 cm2/m2 had a trend to present a higher percentage of severe calcification 
(p=0.14), (table 6), that was not statistically significant.  
 
 
 
 
 
Mismatched 
Bioprosthesis 
(n=9) 
No Mismatched 
Bioprosthesis 
(n=86) 
p  values  by 
bivariable analysis 
Type of bioprosthesis   
lesion: 
 
  0.8 
Aortic  stenosis  3 (33.3%) 22 (25.6%)  
Aortic regurgitation   4 (44.4%) 48 (55.8%)  
Double lesion  2 (22.2%) 16 (18.6%)  
Bioprosthesis leaflet tear  8 (88.9%) 65 (75.6%) 0.7 
Severe bioprosthesis 
calcification 
 3 (33.3%) 12 (14.0%) 0.14 
Table 6. Data of the explanted bioprosthesis for structural valve deterioration. 
Mismatched prosthesis: indexed effective orifice area ≤0.70 cm2/m2. 
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7. Discussion 
 
7.1 Comment 
 
All biological substitutes of heart valves undergo a process of SVD, which represents 
the main determinant of their longevity. Indeed, the current guidelines of the European 
Association Cardiothoracic Surgery/ European Society of Cardiology
80
 and the 
American College of Cardiology/American Heart Association
81
 on management of heart 
valve disease , suggest implanting  aortic bioprosthesis in patients >65 years (class IIa), 
whose lifespan is supposed to be lower than the durability of the bioprosthesis itself. 
When the opposite happens, patients may require the replacement of the deteriorated 
valve prosthesis, a common event with first bioprosthesis generation. 
In our database, 100% (n=96) of the reoperations for SVD were recorded in patients 
receiving a porcine bioprosthesis, and 97% (n=93) of these bioprostheses were Hancock 
standard. Thus, for statistical reasons (lack of model convergence), the first 
multivariable analysis developed to identify predictors of reoperation for bioprosthesis 
deterioration, could not include the variable “type of bioprosthesis”, neither the variable 
“model of bioprosthesis”. For this reason, a propensity score was computed with 9 
variables, including the two ones mentioned above and used for multivariable 
adjustment. Thus, the propensity score analysis was performed to balance and mitigate 
the effect of observed covariates between the PPM and no-mismatch groups. 
Also, because our study population underwent surgery along a 35 years period, it was 
decided to force the variable “date of surgery”, used as dichotomic variable, into the 
multivariable cox regression analysis for computation of predictor of reoperation.  
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The fact that the population receiving the Hancock standard was, almost exclusively, the 
one at risk of reoperation for SVD cannot be explained just by the higher deterioration 
rate which has been already documented in first generation porcine bioprosthesis
82
. 
In fact, the relatively high number of events in this group of patients, should be viewed 
in the light of three statistical considerations: patients with Hancock standard prosthesis 
represent, by far, the largest group of the sample population (57.1%), the youngest one, 
and the one with the largest follow-up (implantation years for each prosthesis and mean 
age of each group of patients are indicated in table 1). 
Historically, the Hancock standard was used at our Institution in the seventies as the 
ideal choice in young patients and fertile women. Later, and because of the not 
convincing outcomes in terms of degeneration rate, the use of this bioprosthesis was 
mainly applied to patients over 65 years of age.  These patients, since the 1980s, 
received the second generation bioprosthesis which had some advantages such as lower 
implant profile and a more sophisticated process of glutaraldheyde fixation and 
antimineralization treatment. For this reason, in our database, second generation 
prostheses were implanted in the oldest group of the sample population, which is also 
the smallest one, and the one with the shortest follow-up time. 
In any case, the deterioration rate of Hancock standard bioprosthesis has produced 
enough number of events for risk factors analysis.  In particular our model identified 
two predictors: age of the patients and IEOA ≤0.70 cm2/m2. Thus, according to our 
multivariable model, the younger the patients at the moment of the aortic valve 
replacement, the higher the risk of undergoing bioprosthesis replacement because of 
SVD. At the same time, patients with IEOA ≤0.70 cm2/m2 were twice as likely to 
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undergo reoperation for SVD than those with IEOA >0.70 cm
2
/m
2
. The propensity score 
adjusted model showed  a not significant trend with similar findings. 
We failed to show the IEOA used as continuous variable or as categorical variable with 
the specific cut off ≤0.85 cm2/m2 and ≤0.65 cm2/m2 has an impact on incidence of 
reoperation because of SVD. Looking at figures 2B and 2C, it is possible to note that in 
both cases patients with moderate (IEOA ≤0.85 cm2/m2) or severe (IEOA ≤0.65 
cm
2
/m
2
) mismatch present with a lower freedom from reoperation compared with 
patient without mismatch. But this difference did not reach statistical significance. 
There are two hypotheses which could explain this result. By one hand there could be a 
statistical power issue. In others words, the variable severe PPM and moderate PPM 
could have maintained their statistical significance in a larger sample population. In 
fact, only 18 patients in the analysis present with severe PPM (IEOA ≤0.65 cm2/m2). 
On the other hand, if we analyze the cumulative frequency distribution and the normal 
plot of the IEOA (fig 1A and 1B) we can observe an almost perfect normal distribution 
around its mean value (0.81 cm
2
/m
2
) with a standard deviation of 0.11 cm
2
/m
2
. This 
means that the values are very well grouped around the mean. Thus the mean value of 
IEOA of the patients with IEOA ≤0.85 cm2/m2 is 0.75, and the mean value of IEOA of 
the patients with IEOA>0.85 cm
2
/m
2 
is 0.93. We can speculate that the difference of 
0.18 cm
2
/m
2
 between the IEOA of the two groups of patients could be too small to show 
an impact in terms of rate of reoperation. 
For this reason we thought that using an intermediate cut-off value of IEOA (0.70 
cm
2
/m
2
) could have given the correct number of patients to solve the problem of 
statistical power. Also, the difference in terms of IEAO between the group with IEOA 
≤0.70 cm2/m2  and the group with IEOA >0.70 cm2/m2 was 0.20 cm2/m2. This value was 
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large enough to create a visible difference in terms of rate of reoperation between the 
two groups. 
The variable, patients’ age, has been previously documented in literature as a risk factor 
for SVD
83
 
84
 
85
. Earlier SVD in young patients undergoing AVR has been classically 
related to the higher tissue valve hemodynamic stress
86
. Recently, SVD has been 
interpreted as a consequence of the intimate host-valve interaction process which, 
through specific genetic expression, can lead to activation of inflammation pathways. 
These phenomena are related to the calcification process which is a typical event in the 
SVD
87
. Young patients may be more exposed to these phenomena, and therefore to the 
risk of SVD. Also, SVD events are much more frequent in young patients undergoing 
AVR because these patients have a larger follow-up time than the older ones. For 
example, the follow-up mean time of our patients under 60 years old is 9.2 years. That 
one of our patients over 60 years old is 5.6 years. Thus, younger patients have an 
observation time, which is the period where it is possible to observe a time related 
event, almost double than that one of the older patients. In conclusion, the larger the 
follow-up time, the higher the probability to observe SVD. 
The second risk factor is patient-prosthesis mismatch. Patients suffering from PPM have 
been traditionally documented to show a worse survival, compared with controls, after 
AVR
88
. Lack of left ventricle mass regression and persistence of higher transvalvular 
gradients, could be the hemodynamic basis of this event
89
.  
Recently, Flameng et al.
90
 from Leuven University have shown the association between 
mismatch and higher incidence of bioprosthesis deterioration. The study analyzed 
echocardiographic and clinical follow-up data of a sample population 564 patients 
undergoing AVR from 1991 to 2003.  Freedom from SVD, which was diagnosed on 
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echocardiographic findings, was 86.2% (40 patients) at 10 years. SVD was classified in 
stenosis type and regurgitation type. In the first case the bioprosthesis had to present 
with leaflet calcification o trans-prosthesis gradient > 55 mmHg. In the regurgitation 
type an increase of bioprosthesis regurgitation compared with the first post-operative 
echocardiography was documented (without calcification o severe gradient).  According 
to this study SVD was prevalently “stenosis type” in patients with PPM (IEOA ≤0.85 
cm
2
/m
2
). Also, according to multivariable analysis, independent predictors of SVD were 
PPM (HR 2.29,) anticalcification treatment (HR 0.34) and prosthesis size < 21mm ( HR 
2.35). Flameng et al. failed, as we did, to show that PPM is an independent risk factor 
for hospital mortality (5%) and for late mortality (survival at 10 year was 47.9%). In 
fact, the only predictor of early and late mortality was age of the patients (p value=0.010 
and   0.0004 respectively). 
These findings were later confirmed by a larger retrospective analysis carried out by the 
same group on 648 patients
91
. The authors speculated that PPM may predispose SVD 
through a process induced by abnormal flow profiles and prosthesis stress distribution.  
There are several methodological differences between our study and that one of the 
group of Leuven University. We were not able to identify most of the echocardiographic 
data of the patients undergoing surgery in the seventies and in the eighties. For this 
reason, we were forced to use the rate of bioprosthesis explantation because of SVD 
instead of SVD diagnosed by echocardiography. In other words, in our patients we can 
image this chronological sequence: 1) bioprosthesis aortic valve implantation; 2) 
possible development of SVD; 3) diagnosis of SVD by echocardiography; 4) possible 
reoperation to replace the deteriorated bioprosthesis because of SVD. Flameng analyzed 
the incidence of the SVD diagnosed by echocardiography (point 3). We analyzed the 
rate of reoperation of deteriorated bioprosthesis (point 4). Thus we had to accept the risk 
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of underestimating the incidence of SVD. In fact we could have missed patients with an 
initial SVD, detectable by echocardiography (which data are missing), but not severe 
enough to require reoperation. 
 Our higher number of events (n=93) is probably due to the analysis of a population 
younger than that one analyzed by the Leuven University (57.9±19.1 years versus 
73.6±5years). We also used a more strict IEOA cut off value for diagnosis of PPM 
(IEOA ≤0.70 cm2/m2). The variable “anticalcification treatment” was not analyzed 
because almost all the events occurred in the group receiving a first generation 
bioprosthesis (without anticalcification treatment). Despite these methodological 
differences our analysis suggested similar results: PPM seems to increase independently 
the risk of SVD. In particular if we compare the analysis of incidence of SVD events of 
the study by Flameng et al.
74
 with our analysis (fig. 2 and 3) we can observe that in both 
cases the curves of patients with PPM and without PPM start diverging since the second 
post-operative year. Thus, patients with mismatch present with higher incidence of SVD 
events since the first years after surgery. The maximum divergence between the two 
curves is observable at about 9-10 years in the study of Flameng 
74
 and at about 12 years 
in our study.  
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Fig 3. Nonparametric Turnbull estimate plotting freedom from structural valve 
deterioration. From Flameng et al. [74] 
 
 
 
Behind 12 years in the Flameng
74
 analysis and behind 15 years in our study, the 
divergence of the two curves starts gradually disappearing. In other words, SVD events 
in Flameng study
74
 are visible earlier.  
This difference in term of time of SVD presentation is probably due to the fact that we 
used as definition of SVD its clinical consequence: reoperation. Flameng used a 
definition based on a specific echocardiographic pattern, so his analysis was able to 
detect the SVD of bioprosthesis before this event may produce the necessity of a 
reoperation. 
This hypothesis is corroborated by the second study about mismatch of Flameng
75
  
which showed (figure 4) the relation between freedom from reoperation and freedom 
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from SVD. This analysis shows clearly that echocardiographic diagnosis of SVD 
anticipates the need of reoperation. 
 
 
Fig.4. Freedom from reoperation (solid line) and SVD (dashedline). From Flameng et 
al. [75] 
 
Important differences between the two analyses are present in term of overall freedom 
from SVD events. In our analysis at 10 years about 74 % of the population is free from 
reoperation for SVD. In the study of  Flameng et.
74
, at ten years about 86% of the 
population is free from SVD. This difference in term of freedom from SVD events, 
could be the expression of one important fact: almost 60% of our population is 
represented by young patients (mean age: 45.1 years) who received the first generation  
bioprosthesis (Hancock I, implanted from 1974 to 1982), the one with the highest 
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incidence of SVD.  The Flameng series starts from 1991, and it is constituted by 
patients > 70 years old who received a second or a third generation bioprosthesis, which 
have anticalcification treatment and, consequently, a longer durability. 
Because of the low number of mortality events, we were not able to carry out an 
appropriate analysis of the impact of PPM on 30-day survival. In fact, only 25 death 
events were recorded and, among the dead patients, only 3 presented with mismatch. 
The percentages of death events in each group were almost identical: 3 of the 47 
patients with mismatch (6.4%) and 22 of the 340 patients without mismatch (6.5%) died 
in first 30 days after surgery. Thus no further analysis is allowed in this case. 
As previously mentioned, we failed also to show an impact of mismatch on long term 
mortality. According to our multivariable model there were 4 independent predictors of 
late mortality: age, female sex, ejection fraction, and urgency. Thus, PPM was not a 
predictor of long-term mortality. According to Kaplan-Meier analysis, 10 year survivals 
of the group with PPM and the group without PPM were 60.5 ± 12.4% and 74.0 ± 3.0 
%. This difference did not reach statistical significance, although this could have been 
due to the limited sample size. These data are consistent with the literature. The 
previously mentioned study of Flameng 
74
, despite analyzing a much lager sample 
population (n=564) than ours (n=387) identified, as the only risk factor for mortality, 
the variable “age of the patients”.  Looking at table 1 (page 18), which resumes the 
largest reports on PPM,  it is  possible to observe that, among the 19 studies analyzing 
long term survival, only 5 were able to show an impact of PPM on late mortality. 
Among the studies considered worthy of further comment and because of the large 
sample population evaluated and completeness of the statistical analysis, the following 
are included. Blackstone et al. 
36
 analyzed, by balancing score risk adjustment, a sample 
population of 13,258 patients undergoing AVR. In this study, an IEOA <1.2 cm
2
/m
2
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was shown to increase 30- day mortality by 1-2%. Yet, the study was unable to detect 
PPM as a risk factor for intermediate or long-term survival. It was speculated that the 
multifactorial nature of the reduced survival after AVR (anticoagulation- related 
complications, limited age span in elderly patients) may mask the impact of PPM on 
long-term mortality. A similar conclusion was reached by Moon et al.
48
, who reported 
that PPM was associated with an impaired late survival only in patients aged <60 years. 
Most likely, Bridges et al. 
35
 have reported the largest study concerning PPM, by 
analyzing data acquired from a total of 42,310 patients undergoing isolated AVR. 
Prostheses with a small geometric orifice area or EOA were reported to be associated 
with an increased operative mortality. The most important finding of this study was that, 
among patients receiving the same model and size of prosthesis, those patients with a 
larger BSA had better outcomes. The authors suggested that the protective effect of a 
large BSA, which probably was related to surgical implant advantages, appeared more 
important than the hypothetical negative effect of PPM on survival. In conclusion, the 
impact of PPM on late mortality may be less important than several unmeasured 
confounding variables, including BSA. 
Also we should remind that in our series only 40% of the deaths during follow-up were 
cardiac events.  Thus in most of the cases, PPM could not play any role in late 
mortality. For all these reasons, we think that post-operative mismatch plays a minor 
role, if any, in long-term survival. The hypothetical negative impact which PPM could 
play in late mortality could be eclipsed by heavier risk factors, such as age of patients, a 
predictor of mortality present in most of long term analysis in valve surgery. 
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7.2 Conclusions 
 
The incidence of mismatch defined as IEOA ≤0.85 cm2/m2 in our population was 66.7% 
(n=258), while the incidence of mismatch defined as IEOA ≤0.65 cm2/m2 was 5.2% 
(n=20). Forty-seven patients (12.1%) presented with IEOA ≤0.70 cm2/m2. 
According to our multi-variable analysis patient-prosthesis mismatch was not an 
independent risk factor for 30-day mortality or for long-term mortality, independently 
from the type of IEAO variable analyzed (continuous variable or categorical variable 
according to the three cut-off values: IEOA ≤0.85cm2/m2, IEOA ≤0.70cm2/m2 and 
IEOA ≤0.65cm2/m2). 
Our analysis suggests that two variables could play an important role in the 
degeneration process of heart valve bioprosthesis: the age of the patients at the time of 
aortic valve implantation, and the presence of mismatch. However, after propensity 
score adjustment, the statistical signification of mismatch was lost. This means that 
factors leading to mismatch, rather than mismatch itself, could be responsible of the 
process of structural valve deterioration. In any case the association we have 
documented could add one more mosaic tile in the understanding of the degeneration 
process of cardiac bioprostheses. We were not able to show any impact of PPM on early 
and late mortality. 
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Conclusiones 
La incidencia en nuestra población del desajuste paciente-prótesis, definido por un 
AEOI ≤0,85 cm2/m2 fue  del 66,7% (n=258); la incidencia del desajuste definido por un 
AEOI ≤0,65 cm2/m2 fue del 5,2% (n=20). Cuarenta y siete pacientes (12,1%) 
presentaron un AEOI ≤0,70 cm2/m2. 
Según nuestro análisis multi-variable, el desajuste paciente-prótesis no fue un factor de 
riesgo independiente de mortalidad a corto o a largo plazo, tanto si se analizó como 
variable continua como si se estudió de manera categórica ( AEOI ≤0,85cm2/m2, AEOI 
≤0,70cm2/m2 y AEOI ≤0,65cm2/m2). 
Nuestro análisis sugiere que dos variables podrían tener un papel importante en la 
degeneración de la bioprótesis aortica: la edad del paciente a la hora del RVA y la 
presencia de desajuste paciente-prótesis (AEOI ≤0,70cm2/m2). De todas formas, después 
del ajuste con el propensity score, la significatividad de la variable “desajuste paciente-
prótesis” se perdió. Esto quiere decir que los factores que producen el desajuste, más 
que el desajuste mismo, pueden ser responsables del proceso de degeneración 
estructural de la bioprótesis. De todas formas, la asociación que documentamos puede 
añadir otro elemento en la comprensión del proceso de degeneración de las bioprótesis. 
No hemos podido demostrar ningún impacto del desajuste paciente-prótesis sobre la 
mortalidad precoz o tardía post operatoria. 
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7.3 Limitations 
 
Given that there were not echocardiographic studies available of patients operated on 
between 1974 and 1986, we studied the incidence of reoperation because of SVD, an 
outcome that could be jeopardized by its subjective nature. 
The indication to replace the aortic bioprosthesis was based on the quantitative 
evaluation of gradients, and on the qualitative clinical evaluation of the patient. 
Reoperation is a medical decision and therefore is subjected to bias. 
The relative small size of the sample population and particularly the low number of 
patients with mismatch (12.1% of the whole sample population), limited the statistical 
power of the study especially on survival analysis. 
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8. Summary 
 
Patient-prosthesis mismatch (PPM) has been identified as a risk factor for mortality 
after aortic valve replacement. Recently PPM has been also reported to increase the risk 
of structural valve degeneration (SVD) in patients receiving a bioprosthetic aortic valve.  
The aim of the present study was to compare the incidence of reoperation because of 
SVD in patients with mismatch to that of a population without mismatch.   
Methods: In total, 387 adult patients undergoing aortic valve replacement with a 
bioprosthesis from 1979 to 2009 were retrospectively reviewed. Our mismatch analysis 
was focused on IEOA studied as continuous variable and as categorical variable. In 
particular we used three cut-off values: IEOA ≤0.85cm2/m2, IEOA ≤0.70cm2/m2 and 
IEOA ≤0.65cm2/m2. The median follow-up period was 7.2 years. Follow-up was 97% 
complete.  
Results: Of the whole sample population, 66.7% (n=258) presented with IEOA ≤0.85 
cm
2
/m
2
, 12.1% (47) had an IEOA ≤0.70 cm2/m2 and 5.2% (n=20) showed an IEOA 
≤0.65 cm2/m2. Thirty day mortality was 6.5% (total deaths=25). Multivariable logistic 
regression analysis revealed four risk factors of early mortality: urgency surgery, redo 
surgery, female sex and patients’ age. According to Kaplan Meier analysis ten years 
survival of the whole sample population was 74.4 ± 2.8 %. According to multivariable 
Cox regression analysis, there were four independent predictors of long term mortality: 
female sex, left ventricle ejection fraction (protector factors), and patients’ age and 
urgency surgery (risk factors). 
IEOA was not an independent risk factor for 30-day mortality or long term mortality 
neither analyzed as continuous variable nor as categorical variable (IEOA ≤0.85cm2/m2, 
IEOA ≤0.70cm2/m2 and IEOA ≤0.65cm2/m2). 
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Ten years freedom from reoperation for aortic bioprosthesis replacement was 
74.3±3.2%. Thus, during follow-up, 111 patients underwent reoperation for aortic 
bioprosthesis replacement. Causes of aortic bioprosthesis replacement were SVD of the 
bioprosthesis (n=96), paravalvular leak (n=10) and acute endocarditis (n=5). According 
to unadjusted Kaplan-Meier analysis, patients with IEOA ≤0.70cm2/m2 had a higher 
incidence of reoperation because of SVD when compared with patients with IEOA 
>0.70cm
2
/m
2
 (Log-rank test: p =0.05). This result was confirmed by multivariable Cox 
regression analysis which identified two independent predictors of reoperation because 
of SVD: age (HR= 0.967; 95% CI=0.954-0.981; p <0.0001) and IEOA ≤0.70cm2/m2 
(HR=2.16; 95% CI=1.079-4.329; p=0.03). The propensity score adjusted model 
confirmed these results, although the risk factor “IEOA ≤0.70cm2/m2” was associated 
with a” p” value just above the significance limit (patients ‘age: HR= 0.967, 95% CI= 
0.953-0.981,  p <0.0001; PPM: HR= 2.033, 95% CI= 0.962-4.295;  p= 0.06). Thus, 
according to our multivariable models, the younger the patients at the moment of the 
aortic valve replacement, the higher the risk of undergoing reoperation because of SVD. 
At the same time, patients with IEOA ≤0.70cm2/m2 were twice as likely to undergo 
reoperation because of SVD than those with IEOA >0.70cm
2
/m
2
. 
In conclusion, besides the age of the patients, the presence of an IEOA ≤0.70cm2/m2 is 
an independent risk factor for reoperation because of SVD. The propensity score 
adjustment shows that  factors producing an IEOA ≤0.70 cm2/m2 , more than mismatch 
itself, could be a risk factor for
 
reoperation because of SVD. 
. 
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Resumen  
El desajuste paciente-prótesis ha sido identificado como factor de riesgo de mortalidad 
después del reemplazo de la válvula aórtica. Recientemente, este desajuste ha sido 
asociado con un aumento de la tasa de la degeneración estructural de las bioprótesis 
aorticas. El objetivo del presente estudio fue comparar la incidencia de reoperación por 
degeneración estructural de los pacientes con desajuste con los que no presentaban 
desajuste. 
     Se analizaron los datos de 387 pacientes adultos intervenidos con reemplazo valvular 
aórtico con una bioprótesis desde 1979 hasta 2009. Nuestro análisis ha sido enfocado 
sobre el área efectiva de orificio indexado (AEOI) estudiado como variable continua y 
como variable categórica según tres valores de corte: AEOI ≤0,85 cm2/m2, AEOI  ≤0,70 
cm
2
/m
2y AEOI ≤0,65 cm2/m2. La mediana del periodo de seguimiento fue de 7,2 años. 
El seguimiento se completó en el 97% de los pacientes. La incidencia  del desajuste 
paciente-prótesis en nuestra población, definido como AEOI ≤0,85 cm2/m2 fue del 
66,7% (n=258) y la incidencia del desajuste definido por un AEOI ≤0,65 cm2/m2 fue del 
5,2% (n=20). Cuarenta y siete pacientes (12,1%) presentaron un AEOI ≤0,70 cm2/m2. 
La mortalidad a corto plazo fue del 6,5%. La regresión logística multivariable demostró 
cuatro factores de riesgo de mortalidad precoz: cirugía urgente, operación previa, sexo 
femenino y la edad de los pacientes. Según el análisis de Kaplan-Meier, la 
supervivencia a 10 años fue del 74,4±2,8 %. En cuanto a la mortalidad a largo plazo, la 
regresión de Cox identificó cuatro variables asociadas de modo independiente con ella: 
sexo masculino, fracción de eyección del ventrículo izquierda (asociación inversa), la 
edad de los pacientes (asociación inversa) y la cirugía de urgencia.  
 El AEOI no fue un factor de riesgo independiente de mortalidad a corto o a largo plazo, 
tanto si se analizó como variable continua como si se estudió de manera categórica 
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(AEOI ≤0,85 cm2/m2, AEOI ≤0,70 cm2/m2 y AEOI ≤0,65 cm2/m2).     Durante el 
seguimiento, 111 pacientes fueron reintervenidos para reemplazar la bioprótesis. Las 
causas de reoperación fueron degeneración estructural de la bioprótesis (n=96), fuga 
peri-protésica (n=10) y endocarditis aguda (n=5). Según el análisis de Kaplan-Meier, los 
pacientes con AEOI ≤0,70 cm2/m2 presentaron una incidencia más alta de 
reintervención por degeneración estructural comparados con los pacientes con AEOI 
>0,70 cm
2
/m
2
 (Log-rank test: p=0.05). Este resultado fue confirmado por la regresión de 
Cox que identificó dos predictores independientes de degeneración estructural: edad 
(HR= 0,967; 95% IC=0,954-0,981; p <0,0001) y AEOI ≤0,70 cm2/m2 (HR=2,16; 95% 
IC=1,079-4,329; p=0,03). El modelo multivariable ajustado con el propensity 
score, confirmó el valor predictor independiente de la edad, pero la variable “AEOI 
≤0,70 cm2/m2” se asoció a un valor "p" justo por encima de la significación estadística 
(edad: HR= 0,967, 95% IC= 0,953-0,981, p <0,0001; AEOI ≤0,70 cm2/m2: HR= 2,033, 
95% IC= 0,962-4,295; p= 0.06). Según nuestro modelo multivariable, cuanto más joven 
es el paciente en el momento del implante de la prótesis aórtica, mayor es el riesgo de 
ser reintervenido por degeneración estructural de la misma. Además, los pacientes con 
AEOI ≤0,70 cm2/m2 presentan un riesgo doble de ser reintervenidos por degeneración 
estructural comparados con los pacientes con AEOI >0,70 cm
2
/m
2
.  
En conclusión, además de la edad de los pacientes, la presencia de un AEOI ≤0,70 
cm
2
/m
2 
es un factor de riesgo de reoperación por degeneración estructural de la 
bioprótesis, aunque el “propensity score” muestra que posiblemente el AEOI ≤0,70 
cm
2
/m
2 
en sí mismo no es un factor de riesgo, sino lo factores que llevan a la existencia 
de este desajuste entre el tamaño de la prótesis y la superficie corporal del paciente. 
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